Age-Dependent Fecal Bacterial Correlation to Inflammatory Bowel Disease for Newly Diagnosed Untreated Children by Nwosu, Felix et al.
Hindawi Publishing Corporation
Gastroenterology Research and Practice
Volume 2013, Article ID 302398, 7 pages
http://dx.doi.org/10.1155/2013/302398
Research Article
Age-Dependent Fecal Bacterial Correlation to Inflammatory
Bowel Disease for Newly Diagnosed Untreated Children
Felix Chinweije Nwosu,1,2 Lill-Therse Thorkildsen,1 Ekaterina Avershina,2 Petr Ricanek,3,4
Gøri Perminow,5 Stephan Brackmann,6 Morten H. Vatn,6,7 and Knut Rudi2
1 Hedmark University College, Hamar, Norway
2Department of Chemistry, Biotechnology and Food Science, Norwegian University for Life Sciences, A˚s, Oslo, Norway
3Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway
4 EpiGen Institute, Research Centre, Akershus University Hospital, Lørenskog, Norway
5 Pediatric Department, Oslo University Hospital, Ulleva˚l, Oslo, Norway
6 EpiGen Institute, Akershus University Hospital, University of Oslo, Oslo, Norway
7Medical Clinic, Oslo University Hospital, Rikshospitalet, Norway
Correspondence should be addressed to Knut Rudi; knut.rudi@umb.no
Received 9 February 2013; Accepted 1 April 2013
Academic Editor: Devendra Amre
Copyright © 2013 Felix Chinweije Nwosu et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The knowledge about correlation patterns between the fecal microbiota and inflammatory bowel diseases (IBD)—comprising the
two subforms Crohn’s disease (CD) and ulcerative colitis (UC)—for newly diagnosed untreated children is limited. To address this
knowledge gap, a selection of faecal specimens (CD, 𝑛 = 27 and UC, 𝑛 = 16) and non-IBD controls (𝑛 = 30) children (age < 18
years) was analysed utilising bacterial small subunit (SSU) rRNA. We found, surprising age dependence for the fecal microbiota
correlating to IBD.Themost pronounced patterns were thatE. coliwas positively (𝑅2 = 0.16,𝑃 = 0.05) and Bacteroidetes, negatively
(𝑅2 = 0.15, 𝑃 = 0.05) correlated to age for CD patients. For UC, we found an apparent opposite age-related disease correlation
for both Bacteroides and Escherichia. In addition, there was an overrepresentation of Haemophilus for the UC children. From our,
results we propose a model where the aetiology of IBD is related to an on-going immunological development in children requiring
different age-dependent bacterial stimuli. The impact of our findings could be a better age stratification for understanding and
treating IBD in children.
1. Introduction
The human gut microbiota is represented by about 1014
microbes per individual, comprising more than 500 species.
The human gut microbiota is dominated by the members of
the phyla Bacteroidetes and Firmicutes [1, 2]. The interactive
relationship, symbiosis or pathogenic, between the host and
the gut bacteria is shaped by selective pressures within the
host (genetic) and competitivemodulation of residentmicro-
bial community, of which net effect may have implications on
the health of the host [1, 3]. An imbalance in the composition
of the commensals or beneficial (symbiotic) bacteria and
pathogenic bacteria creates an abnormal host microbiota,
which may lead to IBD or other diseased states [4–7].
From various IBD studies, etiologically implicated bac-
teria include Faecalibacterium prausnitzii exerting a positive
impact, described as anti-inflammatory, whileEscherichia coli
and Mycobacterium avium paratuberculosis (MAP) have a
negative impact as potential IBD infectious agents [5, 8–12].
These relations are mainly established from differences in
gut bacterial composition in analysed fecal samples between
observed IBD cases and healthy subjects [2].
The incidence of pediatric onset of IBD is increasing [13].
Compared to adults, there is an overrepresentation of CD
over UC in pediatric patients, while UC is often more severe
in children compared to adults [14]. There are several lines of
evidence for strong disease-related correlation patterns with
the gut microbiota in children [15]. However, the microbiota
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Table 1: Base-called MCR components.
Components (match) Sequences
Comp1 (Faecalibacterium)
AGCGTGTCCGATTTACTGGGTGTAAGGGAGCGCTAGCGGAGAGCAAGTTCG
GAGTGAAATCCATGGGCTCAACCCATGGAARTGCTTTCAAACCTTGMTTTT
CTTTGYTAGTGCAAAGGTAAAGTCGGATRCCTGAGGTGGTACGGGTGGAAT
GCGTAATATTYGGAGGAACACCATGGCAAGGCGGTCRTACTGGGCACCAAC
TGACGRTGAGGCTCAA
Comp2 (designated noise) AGCTAGTATCCGGATTCTARTGGGTGTAAAGGGCGTAGCGGTTATCTAAAGGGCTTTT
Comp3 (Dialister)
AGCGTTGTCCGGATTATTGGGCGTAAAGCGCGCGCAGGCGGCTTTCCRAAGTC
CTCTCTTAAAAGTGCGGGGCTTAACCCCMGYTG
GGGYATGYAACCTGGYAAYCCTGGAGTATCGGAYAGYAAAGMGAGAATTCCAT
AGTGTAGCGGTYAAATGCGTAAGATTAGGAAG
AACACCGGTGGCGAAGGSGACTTTCTGGACAAAACTGACGCTGAGGCGCGAAA
Comp4 (Haemophilus)
AGCGTTATTCGGAATAARTGGGCGTAAAGGGCACGCAGGCGGTGKCTTAAGTG
AGGTGTGAAAGCGCCCGGGCTTAACCTGGGAATMGCATTTCATACTGGGGTGC
CGTAAMTACTTTAGGGAGYGGTAYATATTCTCACGTMGTAGCGGTYAAWGTSC
TTAAGTATGTGAAGYAATACCGAAGGCAGAAGSCARCCCTMGGAWTGTCACGT
GACSRTCATGTGCAAA
Comp5 (Escherichia)
AGCGTTAATCGGAATTACTGGGCGTAAAGCGCACGCGGCGGTTTGTTAAGTCAG
ATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGCTTGA
GTCTCGTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATC
TGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGG
TGCGAAA
Comp6 (Bacteroides)
ACGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGTGGARTTGTTAAGTCA
TGTATGTGAAAGCTTTGCGGCTCAACCGTAAAATTGCATTTGAWACTGGAAGW
CTTGAGTGCAGTAGAGGRAGAGGCGGAATTCCTGGTGTAGCGGTGAAATGCTAA
TATCACGAAGAACATCCGATGTGCGAAGGCGGCTTAGCTGGACTGTAACTGACY
RTGAMGCTCGAAA
related to the onset of the disease is not yet well characterized
[16].
The aim of the current work was to establish the correla-
tion patterns between the composition of the dominant gut
microbiota and IBD in newly diagnosed untreated children.
Our strategy was to use a novel mixed 16S rRNA gene
sequencing approach to describe the overall composition
of the microbiota [17, 18] in combination with full-length
16S rRNA gene clone Sanger sequencing [19] to obtain
strain/species level information.
We present results showing age-related correlations be-
tween gut bacteria and IBD, in addition to average differences
in the microbiota. We also present an explanation model for
our observations.
2. Results and Discussion
2.1. Microbiota Composition in Study Population. Using prin-
cipal component analysis (PCA), evolving factor analysis, and
empirical evaluations, we found that our mixed sequences
were composed of 6main components (explaining themajor-
ity of the variance) representing the dominating phylogroups
in the dataset. These were resolved by Multivariate Curve
Resolution (MCR). Five of the components represented
spectra that could be base called (Table 1), while the sixth
component probably represented noise due to the short
length and lack of match in the Ribosomal Database Project
(RDP) database (not shown). The dominant taxa identified
Table 2: Demographic data.
Disease
group
Number
of
patients
Average
age
Median
duration1 Male (%)
1
CD 27 12.8 0.5 56
UC 16 11.3 0.4 47
Non-IBD 30 11.5 1.5 32
1Adapted from [13].
were Faecalibacterium, Dialister, Haemophilus, Escherichia,
and Bacteroides for MCR components 1, 3, 4, 5 and 6, respec-
tively. These taxa showed a relatively diverse distribution
pattern among the children analysed (Figure 1, Supplemen-
tary Table 1, see Supplementary Material available online at
http://dx.doi.org/10.1155/2013/302398).
Cloning and sequencing confirmed the main composi-
tion detected by MCR (Figure 2, Supplementary Table 2).
In addition, we detected a range of taxa representing minor
constituents in the clone data (Figure 2).
2.2. IBD Correlation to the Dominant Microbiota. The main
age-related trends in the data were both positive (𝑃 = 0.05)
and negative (𝑃 = 0.05) age correlations for Escherichia and
Bacteroides, respectively, for the CD children (Figure 1(c)). In
addition, permutation testing revealed a significant increase
in Bacteroides compared to the control and CD children
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Figure 1: Composition of the gut microbiota as determined by MCR. (a) Individual distribution of the gut microbiota. (b) Average
composition of the gut microbiota within the disease categories analysed. (c) Change of gut microbiota within disease categories with age.
(𝑃 = 0.01), although the slopes were not significantly differ-
ent from zero.
For the nonage-related patterns, Escherichia was under-
represented (𝑃 = 0.05) while Haemophilus was overrepre-
sented (𝑃 = 0.01) inUC, as compared toCDand controls. For
CD, on the other hand, we found an underrepresentation of
Haemophilus (𝑃 = 0.05) (Figure 1(b)).
For the diversity analyses, we did not find any strong
age-related trends, while we found that both Shannon’s 𝐻
and Simpson’s 𝐷 indexes were significantly lower for the CD
subjects compared to the controls (0.32 versus 0.48 𝑃 = 0.05
and −0.46 versus −0.08 𝑃 = 0.04, resp.). For the UC children
we did not find a significantly reduced diversity.
The strain level correlations showed that there were two
clades of Escherichia, one associated with diseased patients
and another associated mainly with one of the control
patients. Furthermore, it suggests that Haemophilus repre-
sents a very tight phylogroup,mainly associatedwith diseased
4 Gastroenterology Research and Practice
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Figure 2: Neighbour joining phylogenetic tree for the nearly full-length sequences obtained in this work. The numbering at the nodes is the
bootstrap support, with the 100% support values highlighted. For each sequence, the colour code indicates the patients diagnosis: green—
control, red—CD, and black—UC.
patients. For CD, we detected a cluster of Enterococcus, while
for UC a cluster of Lactobacillus was detected. These clusters,
however, were only represented by single patients.
2.3. Potential Causes for the IBD Bacteria Correlation. The
apparent opposite age-related trend for Bacteroides and
Escherichia between UC and CD may reflect the differences
in underlying immunological disorders for these diseases.
CD is a Th1 dominated immunological disease, and UC is
a Th2 dominated immunological disease [16]. Therefore, a
possible explanation could be that the immunological effects
of Bacteroides at early age promote CD, while later it would
protect. The development of the immune system in children
is an on-going process potentially requiring different stimuli
at different ages [20]. ForBacteroides fragilis—one of themost
widely studied species within the Bacteroidetes—it has been
shown that this bacterium can produce immunosuppressive
polysaccharides with a potential therapeutic use for CD in
adults [21]. This can explain the protective effect with age,
while immune suppression at an earlier age may promote
the disease. The positive age correlation for Escherichia and
CD can be explained under the same model. It has been
shown that exposure to E. coli early in life can promote the
immune development in a Th1, as opposed to an allergenic
Th2 direction [22–24]. In the adult or adolescent population,
on the other hand, E. coli is associated with ileal CD [25].
Thus, it could be that the immune stimulatory effect at early
age would be important for immune homeostasis, while at a
later age similar stimulations would lead to a dysbiotic CD
state.
We found that overrepresentation of Haemophilus in UC
was interesting.Despite extensive screenings, no studies, have
yet identified this bacterium as important inUC [15], while in
our study this bacterium was significantly correlated to UC.
Themucosal inflammation properties of severalHaemophilus
species and the requirement for blood factors for growth [26]
may suggest that it could be important in the disease onset.
However, further investigations are needed in order to rule
out potential confounders such as water contamination, drug
Gastroenterology Research and Practice 5
Table 3: Biochemical blood test levels and fecal calprotectin1.
Measurement Unit UC CD Non-IBD
ESR mm/h 17 26 5
CRP mg/L 7 22 7
Hemoglobin g/dL 11 11.6 12.5
Hematocrit Fractions 0.35 0.36 0.38
Platelet count 109/L 373 368 268
Leukocytes 109/L 7 8.5 6.8
Neutrophil granulocytes 109/L 4.2 4.7 3.5
ALAT U/L 18 16 24
Alkaline phosphatase U/L 148 106 189
Albumin g/L 42 37 40.5
Calprotectin mg/kg 1181 1250 33
1Average values adapted from [13].
regimes, and collateral diseases. The number of individuals
included in our study is also relatively low.
We found the overall high level of Escherichia in the con-
trol group surprising. This is not expected in a healthy pop-
ulation [27]. However, since our control group was selected
fromchildrenwhowere suspected to have IBD, but eventually
diagnosed as non-IBD, these cannot be considered as rep-
resentatives for the normal healthy population. The control
samples probably represent a heterogeneous population of
different forms of dysbioses since they are recruited based on
IBD symptoms but eventually found to be non-IBD. These
probably include inflammatory bowel syndrome (IBS) cases,
with similarities in symptoms to IBD. Similarly, these subjects
may have been IBD without full manifestation or on the
border of disease development.
In conclusion, the correlation patterns detected may re-
flect the underlying age-related disorders in IBD.
3. Materials and Methods
3.1. Cohort. A total of 75 children samples (<18 years old)
stored at −80∘C were provided from diagnosed patients stool
specimens. Samples were deposited from diagnosed, early
inflammatory bowel disease (IBD) patients at Akershus
University Hospital (Ahus), Oslo, Norway. These were the
children from the Norwegian IBSEN II study for which we
have stool samples. From these collections, 27 were diag-
nosed, Crohn’s disease (CD), 16 diagnosed ulcerative colitis
(UC), and 30 samples were from diagnosed non-IBD subjects
(control). The criteria for diagnosis and detailed information
about the subject are presented in Tables 2 and 3.
IBD diagnosis criteria for patient specimen included in
the IBSEN II cohort were abdominal symptoms including
diarrhea and/or blood in stool for more than 10 days and
endoscopic or radiological examinations for signs of inflam-
mation and histological signs of chronic inflammation.
Subjects with pathogenic gut bacterial infection (except
Mycobacterium avium), parasites, cysts, and eggs were
excluded from this cohort. Similarly, comorbid patients with
cancer, haematological or hepatological disorders, and signif-
icant cardiovascular, neurological, and respiratory conditions
were not included in this study. In addition, other chronic
inflammations were exempted from this study in both disease
and control subjects.
3.2. DNA Purification and Quantification. Between 180 and
220mg of frozen stool (−80∘C) was cut with a scalpel and
transferred to each of 2mL microcentrifuge tubes. These
were mechanically and vigorously lysed with 1.6mL of ASL
buffer (Qiagen, Hilden, Germany) for 2 minutes at 30Hz
using magnetic beads (Qiagen, Hilden, Germany) on Qiagen
TissueLyser (Qiagen, Hilden, Germany) and further lysed at
95∘C for 5minutes in a heating block. For the subsequent pro-
cessing, we followed the recommendations of the producer
(http://www.qiagen.com/MyQIAcube/).
3.3. Polymerase Chain Reaction (PCR) Amplification of 16S
rRNA. An approximately 1200 bp 16S rRNA gene region
covering V3 to V9was PCR amplified as previously described
[28]. The reaction mix contained 1.25 U Hot FirePol (Solis
Biodyne, Tartu, Estonia), 1 × B2 buffer (Solis Biodyne, Tartu,
Estonia), 2.5mM MgCl
2
, 200𝜇M dNTP (Thermo Fisher
Scientific, Surrey, UK) and 0.2 𝜇M each of forward and
reverse primers to approximately 30 ngDNA template in final
volume of 25 𝜇L.ThePCR thermocycler was programmed for
initial denaturation at 95∘C for 15 minutes, with 30 cycles of
denaturation at 95∘C for 30 seconds, annealing for 30 seconds
at 55∘C, elongation for 1 minute and 20 seconds at 72∘C, and
at the end a final elongation for 7 minutes at 72∘C.
3.4.Mixed Sequencing. ThePCR product was firstly prepared
for sequencing by treatment with 3U Exonuclease I (ExoI)
and 8U, shrimp alkaline phosphatase. (USB Corp, OH, USA)
at 37∘C for 2 hours, andwas inactivated at 80∘C for 15minutes.
The ExoSAP treated PCR product was diluted 1/10, then
1 𝜇L was placed in each well and included with 0.32 𝜇M
each of 5󸀠-[C X30]CGTATTACCGCGGCTGCTGGCAC-3󸀠
(U515FC30) primers, 1 × BigDye buffer and 1 ÎĲl, BigDye
v1.1, incorporation reaction to a 10 𝜇L total volume. The PCR
thermocycler was programmed at 25 cycles of denaturation
at 96∘C for 15 seconds, annealing at 50∘C for 5 seconds
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and elongation at 60∘C for 4 minutes. The sequencing
reaction was cleaned using the XTerminator kit following
the manufacturers’ recommendations (Applied Biosystems).
Sequences analysis was on the ABI Genetic Analyzer 3130xl
sequencer with 36 cm capillary array containing polymer 7
(POP-7, Applied Biosystems). Injection time was set at 6
seconds at 90∘C. The sequences generated were base called
by the Sequence Scanner Software v1.0 (Applied Biosystems).
The mixed sequences were resolved using the Multivari-
ate Curve Resolution (MCR) analysis to expose and recover
the pure components in the spectral of sequences. MCR is
a technique to resolve pure spectra. Firstly, an alignment
of all of the mixed sequences spectra was generated and
repeated for preprocessing and normalization taking only
small portions of individual peaks in the spectra to avoid
peak shifts due to differences in retention times. principal
component analyses (PCA) and/or evolving factor analyses
(EFA) determined the number of significant components
explaining the most variations in the dataset. With the
predetermined component number setting, MCRwas run on
the aligned spectra. MCR output is the information on the
relative amount of each component in the individual sam-
ple/sequence in the data set and the base called spectra
information on each component. All the analyses of sequence
spectra were performed using MATLAB R2010a software
(The MathWorks Inc., Natick, MA, USA), Statistical and
Bioinformatics toolboxes for MATLAB. For EFA, PCA, and
MCR analyses, PLS Toolbox v5.8 for MATLAB (Eigenvector
Research Inc., USA) was used.
3.5. Cloning and Full-Length 16S rRNA Gene Sequencing.
Using the MCR resolved sequence components, DNA pools
were empirically selected for cloning from each component,
15 samples in total, corresponding to 3 for each component for
each classification (UC, CD, and control). Amplicon cloning
and DNA sequencing were done as previously described
[18], sequencing both strands. Forward and reverse sequence
reaction results were assembled, aligned, and trimmed for
noise using the CLCGenomicWorkbench Software (CLC bio
A/S, Denmar). Aligned sequences were filtered for chimeric
16S rRNA sequences using the chimeric slayer algorithm in
mothur (http://www.mothur.org/) prior to further analysis.
3.6. Ecological Diversity Analyses. We analysed ecological
diversity using modified versions of Simpson’s 𝐷 and Shan-
non’s𝐻. In our case, we used theMCR components as species
surrogate. The following formula was used for Simpson’s𝐷:
Simpson’s 𝐷 = 1 −∑MCR
𝑖
. (1)
Themodified Shannon’s𝐻was calculated using the following
formula:
Shannon’s 𝐻 = ∑MCR
𝑖
× Log (MCR
𝑖
) , (2)
where MCR
𝑖
is the score for the 𝑖th component.
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